A biologist takes a coronavirus DNA sample from the freezer at the Technological Vaccine Center of the Federal University of Minas Gerais, in Belo Horizonte, Brazil Pedro Vilela/Getty Images
We have a covid-19 vaccine that works. But can we keep it cold enough to get it to enough people? Among Pfizer and BioNTech’s long , which this week was reported to be 90 per cent effective, is the challenge of its “ultra-low temperature formulation”, and how to store and distribute it along the so-called “cold chain”.
Between manufacture and doses…
